biological source
rat
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
CR-1, monoclonal
species reactivity
rat, human, bovine
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable, western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... DPYSL5(56896)
Immunogen
CRMP-5 purified from rat and human brain.
Application
Anti-Collapsin Response Mediated Protein 5 Antibody, clone CR-1 detects level of Collapsin Response Mediated Protein 5 & has been published & validated for use in WB, IH.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Growth Cones & Axon Guidance
Growth Cones & Axon Guidance
Western blot: 1:500-1:2,000 on human and rat brain extracts. 1:500-1:2,000 on human small-cell lung carcinoma. 1:1,500-1:6,000 on bovine retina and optic nerve extracts.
Immunohistochemistry: 1:50-1:200 on bovine retina frozen sections fixed with 10% formalin. No reactivity on mouse cerebellum.
Protein isolation: Bound to Bio-Rad′s Affi-gel (cat# 153-6046) to pull out native CRMP-5 from aqueous extracts of brain.
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 1:50-1:200 on bovine retina frozen sections fixed with 10% formalin. No reactivity on mouse cerebellum.
Protein isolation: Bound to Bio-Rad′s Affi-gel (cat# 153-6046) to pull out native CRMP-5 from aqueous extracts of brain.
Optimal working dilutions must be determined by end user.
Biochem/physiol Actions
Collapsin response mediated protein-5 (CRMP-5). The antibody binds to a region of the human protein from between ~369 to 564 amino acids.
Physical form
Unpurified tissue culture supernatant from a perfusion system, filtered through a 0.2μ micron membrane prior to vialing. Product contains 20%FBS and Ciprofloxacin at final concentration of 10μg/mL.
Preparation Note
Maintain at -20°C in undiluted aliquots for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles.
Uses of the CR-1 and CR-3 antibodies are covered under pending patent application(s) assigned to the Mayo Foundation for Medical Education and Research (MFMER) and are proprietary to MFMER. Academic not-for-profit research institutions are granted an automatic license with the purchase of this product to use the antibody only for internal, non-sponsored, non-commercial, academic research purposes which license specifically excludes the right to sell, or otherwise transfer the antibody or its derivatives to third parties. In accepting this license, all users acknowledge that the CR-1 and CR-3 antibodies are experimental in nature. MFMER makes no warranties, express or implied of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the CR-1 and CR-3 antibodies, patents or product. All others are invited to request a license from MFMER prior to purchasing this antibody or using it for any purpose. For license information, please contact Mayo Medical Ventures, Office of Technology Commercialization at (507) 284-8878.
Uses of the CR-1 and CR-3 antibodies are covered under pending patent application(s) assigned to the Mayo Foundation for Medical Education and Research (MFMER) and are proprietary to MFMER. Academic not-for-profit research institutions are granted an automatic license with the purchase of this product to use the antibody only for internal, non-sponsored, non-commercial, academic research purposes which license specifically excludes the right to sell, or otherwise transfer the antibody or its derivatives to third parties. In accepting this license, all users acknowledge that the CR-1 and CR-3 antibodies are experimental in nature. MFMER makes no warranties, express or implied of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the CR-1 and CR-3 antibodies, patents or product. All others are invited to request a license from MFMER prior to purchasing this antibody or using it for any purpose. For license information, please contact Mayo Medical Ventures, Office of Technology Commercialization at (507) 284-8878.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Gladiola Goranci-Buzhala et al.
Cell reports, 31(10), 107738-107738 (2020-06-11)
Glioblastoma (GBM) possesses glioma stem cells (GSCs) that exhibit aggressive invasion behavior in the brain. Current preclinical GBM invasion assays using mouse brain xenografts are time consuming and less efficient. Here, we demonstrate an array of methods that allow rapid
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持